ImmunoCellular Therapeutics has signed a research agreement with George Mason University for the development of a blood test designed to detect small cell lung cancer and pancreatic cancer using ImmunoCellular’s monoclonal antibody technology. According to the agreement, the blood-based test would be designed to look for certain markers, potentially allowing for early detection of cancers as well as assisting in the selection of patients most likely to respond to the company’s monoclonal antibody therapy, ICT-109.